Cargando…
Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive pat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519796/ https://www.ncbi.nlm.nih.gov/pubmed/26239682 http://dx.doi.org/10.3390/jcm4071380 |
_version_ | 1782383555887759360 |
---|---|
author | Mrejen, Sarah Jung, Jesse J. Chen, Christine Patel, Samir N. Gallego-Pinazo, Roberto Yannuzzi, Nicolas Xu, Luna Marsiglia, Marcela Boddu, Sucharita Freund, K. Bailey |
author_facet | Mrejen, Sarah Jung, Jesse J. Chen, Christine Patel, Samir N. Gallego-Pinazo, Roberto Yannuzzi, Nicolas Xu, Luna Marsiglia, Marcela Boddu, Sucharita Freund, K. Bailey |
author_sort | Mrejen, Sarah |
collection | PubMed |
description | With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with treatment-naïve NVAMD initially classified based on fluorescein angiography (FA) alone or with an anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed over an average of 3.5 years (range 1–6.6) with a retention rate of 62.9%, and visual acuity significantly improved with a TER that required a mean number of 8.3 (±1.6) (± standard deviation) intravitreal anti-VEGF injections/year (range 4–13). The number of injections and the anatomic classification were independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1 neovascularization had better visual outcomes and received more injections than the other neovascular subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes. |
format | Online Article Text |
id | pubmed-4519796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-45197962015-07-30 Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration Mrejen, Sarah Jung, Jesse J. Chen, Christine Patel, Samir N. Gallego-Pinazo, Roberto Yannuzzi, Nicolas Xu, Luna Marsiglia, Marcela Boddu, Sucharita Freund, K. Bailey J Clin Med Article With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with treatment-naïve NVAMD initially classified based on fluorescein angiography (FA) alone or with an anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed over an average of 3.5 years (range 1–6.6) with a retention rate of 62.9%, and visual acuity significantly improved with a TER that required a mean number of 8.3 (±1.6) (± standard deviation) intravitreal anti-VEGF injections/year (range 4–13). The number of injections and the anatomic classification were independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1 neovascularization had better visual outcomes and received more injections than the other neovascular subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes. MDPI 2015-07-08 /pmc/articles/PMC4519796/ /pubmed/26239682 http://dx.doi.org/10.3390/jcm4071380 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mrejen, Sarah Jung, Jesse J. Chen, Christine Patel, Samir N. Gallego-Pinazo, Roberto Yannuzzi, Nicolas Xu, Luna Marsiglia, Marcela Boddu, Sucharita Freund, K. Bailey Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration |
title | Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration |
title_full | Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration |
title_fullStr | Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration |
title_full_unstemmed | Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration |
title_short | Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration |
title_sort | long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519796/ https://www.ncbi.nlm.nih.gov/pubmed/26239682 http://dx.doi.org/10.3390/jcm4071380 |
work_keys_str_mv | AT mrejensarah longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT jungjessej longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT chenchristine longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT patelsamirn longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT gallegopinazoroberto longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT yannuzzinicolas longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT xuluna longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT marsigliamarcela longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT boddusucharita longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration AT freundkbailey longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegeneration |